JP2020528885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528885A5 JP2020528885A5 JP2020502320A JP2020502320A JP2020528885A5 JP 2020528885 A5 JP2020528885 A5 JP 2020528885A5 JP 2020502320 A JP2020502320 A JP 2020502320A JP 2020502320 A JP2020502320 A JP 2020502320A JP 2020528885 A5 JP2020528885 A5 JP 2020528885A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- inhibitor
- immune
- hematopoietic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024102476A JP2024123210A (ja) | 2017-07-19 | 2024-06-26 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534537P | 2017-07-19 | 2017-07-19 | |
| US62/534,537 | 2017-07-19 | ||
| US201862628733P | 2018-02-09 | 2018-02-09 | |
| US62/628,733 | 2018-02-09 | ||
| PCT/US2018/042822 WO2019018603A2 (en) | 2017-07-19 | 2018-07-19 | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102476A Division JP2024123210A (ja) | 2017-07-19 | 2024-06-26 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528885A JP2020528885A (ja) | 2020-10-01 |
| JP2020528885A5 true JP2020528885A5 (cg-RX-API-DMAC10.html) | 2021-08-26 |
Family
ID=63104133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502320A Pending JP2020528885A (ja) | 2017-07-19 | 2018-07-19 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2024102476A Pending JP2024123210A (ja) | 2017-07-19 | 2024-06-26 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102476A Pending JP2024123210A (ja) | 2017-07-19 | 2024-06-26 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12036241B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3654986A2 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2020528885A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019018603A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| RS61406B1 (sr) | 2014-06-06 | 2021-03-31 | Bluebird Bio Inc | Poboljšane kompozicije t ćelija |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| MX2019005277A (es) | 2016-11-04 | 2019-09-27 | Bluebird Bio Inc | Composiciones de celulas t con car anti-bcma. |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| US12036241B2 (en) | 2017-07-19 | 2024-07-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3914267A1 (en) | 2018-01-25 | 2021-12-01 | Mia Levite | Methods for improved immunotherapy |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| WO2020092792A2 (en) * | 2018-10-31 | 2020-05-07 | Oncotracker, Inc. | Method of enhancing immune-based therapy |
| WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| AU2020254699A1 (en) * | 2019-04-05 | 2021-12-02 | 2Seventy Bio, Inc. | Manufacturing anti-BCMA CAR T cells |
| GB201909573D0 (en) * | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| GB201911958D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Methods of t cell production |
| JP7879804B2 (ja) * | 2019-12-06 | 2026-06-24 | フェイト セラピューティクス,インコーポレイテッド | 小化合物を使用するiPSC由来エフェクター免疫細胞の増強 |
| FR3108501A1 (fr) * | 2020-03-27 | 2021-10-01 | Universite De Paris | « Nouvelles cibles thérapeutiques à effet anti-inflammatoire et anti-interféron ». |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN111454903B (zh) * | 2020-05-06 | 2023-10-20 | 青岛瑞思德生物科技有限公司 | 免疫细胞体外培养、诱导、激活、冻存方法及其细胞库建立 |
| KR102594083B1 (ko) | 2020-07-07 | 2023-10-25 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| WO2022120247A1 (en) * | 2020-12-04 | 2022-06-09 | Fate Therapeutics, Inc. | Off-the-shelf ipsc-derived nk cell therapy for hematological cancer treatment |
| US20240150755A1 (en) * | 2021-02-26 | 2024-05-09 | Salk Institute For Biological Studies | Modulating regulatory t cell function in autoimmune disease and cancer |
| US20240307540A1 (en) * | 2021-07-02 | 2024-09-19 | Fate Therapeutics, Inc. | Protected effector cells and use thereof for allogeneic adoptive cell therapies |
| CN116270588B (zh) * | 2022-12-26 | 2025-07-25 | 中国科学技术大学 | Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用 |
| WO2024148402A1 (en) * | 2023-01-12 | 2024-07-18 | Peter Maccallum Cancer Institute | A method of preparing cells for adoptive cell therapy |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
| CN119112823A (zh) * | 2024-08-15 | 2024-12-13 | 吉林大学 | 一种仿生纳米复合材料及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| RS61406B1 (sr) | 2014-06-06 | 2021-03-31 | Bluebird Bio Inc | Poboljšane kompozicije t ćelija |
| US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| IL292504B2 (en) * | 2015-10-20 | 2024-01-01 | Kite Pharma Inc | -methods of preparing t cells for t cell therapy |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| US12036241B2 (en) | 2017-07-19 | 2024-07-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
-
2018
- 2018-07-19 US US16/631,781 patent/US12036241B2/en active Active
- 2018-07-19 JP JP2020502320A patent/JP2020528885A/ja active Pending
- 2018-07-19 EP EP18750040.0A patent/EP3654986A2/en active Pending
- 2018-07-19 WO PCT/US2018/042822 patent/WO2019018603A2/en not_active Ceased
-
2024
- 2024-06-26 JP JP2024102476A patent/JP2024123210A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502722A5 (cg-RX-API-DMAC10.html) | ||
| JP2019502725A5 (cg-RX-API-DMAC10.html) | ||
| US12036241B2 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| US20240408200A1 (en) | Methods of cell culture for adoptive cell therapy | |
| Couture et al. | HLA-class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy | |
| JP2025038093A (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| US11932870B2 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| AU2022202172A1 (en) | Improved methods of cell culture for adoptive cell therapy | |
| Wrzesinski et al. | Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells | |
| Liu et al. | Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity | |
| Robertson et al. | Interleukin 12: basic biology and potential applications in cancer treatment | |
| JP2020513243A5 (cg-RX-API-DMAC10.html) | ||
| JP7668781B2 (ja) | 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法 | |
| IL293564A (en) | Enhancement of an effector immune cell, derived from an induced pluripotent stem cell, using small molecules | |
| CA3123467A1 (en) | Production and therapeutic use of off-the-shelf double negative t cells | |
| CN118871572A (zh) | 使用多种t细胞受体对干细胞t细胞进行工程化 | |
| Ritter et al. | Effects of interleukin-12p40 gene transfer on rat corneal allograft survival | |
| CN117979978A (zh) | 从干细胞产生经工程化的t细胞 | |
| JP2024517966A (ja) | 同種異系car t細胞療法のために幹細胞を操作すること | |
| US20260071180A1 (en) | Genetically engineered placental mucosalassociated invariant t (mait) cells and uses thereof | |
| Liao et al. | Mesenchymal stem cells and their immunomodulatory properties | |
| HK40119436A (en) | Genetically engineered placental mucosal-associated invariant t (mait) cells and uses thereof | |
| Kawamoto et al. | Cloning and expansion of antigen-specific T cells using iPS cell technology: Possible use of regenerated T cells in personalized medicine | |
| Cardoso | Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well? | |
| Rotte et al. | Promising immunotherapeutic approaches in clinical trials |